Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeu...
Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions
MITI will develop and mature a novel, ground-breaking technology for high precision non-ionizing metabolic imaging, enabling fast and non-invasive detection of the markers of metabolic processes e.g., cell proliferation and energy...
MITI will develop and mature a novel, ground-breaking technology for high precision non-ionizing metabolic imaging, enabling fast and non-invasive detection of the markers of metabolic processes e.g., cell proliferation and energy metabolism. Using the results of metabolic imaging, medical specialists will be able to establish the effectiveness of therapies and determine the specific disease months sooner than is possible with currently available technologies. This will increase patient well-being and reduce the costs of healthcare as unsuccessful therapies can be stopped and replaced earlier by more effective (personalised) therapies. This solution addresses an enormous market with millions of patients worldwide. MITI builds on the results of NICI in which the basic key marker molecules for metabolic imaging on MRI platforms were successfully discovered (1H, 2H, 31P and 23Na), including the capability to detect these by inserts on 7T MRI platforms. MITI comprises: 1. The further development and testing of a basic double tuned metabolic imaging set (detecting 1H and one of the following molecules: 2H or 31P or 23Na). 2. Validation of the basic technology to detect metabolic markers in specific use cases: - cell proliferation metabolism after treatment of lung tumours and pancreatic cancer with liver metastases; - cardiac drug mechanisms; - energy metabolism of muscle dystrophy. 3. Development of an advanced quadruple tuned metabolic imaging set that will broaden the spectrum of metabolic processes that can be successfully viewed in parallel. The results of the use cases will be used for power calculations for clinical trials to be conducted after MITI. The MITI partners aim to commercialize the technology, directly after MITI by providing it to clinicians in research centres and within 3 years after MITI to general medical centres.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.